ER calcium depletion as a key driver for impaired ER-to-mitochondria calcium transfer and mitochondrial dysfunction in Wolfram syndrome
-
Published:2024-07-21
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Liiv MailisORCID, Vaarmann AnnikaORCID, Safiulina DzhamiljaORCID, Choubey VinayORCID, Gupta Ruby, Kuum Malle, Janickova LuciaORCID, Hodurova Zuzana, Cagalinec MichalORCID, Zeb Akbar, Hickey Miriam A.ORCID, Huang Yi-LongORCID, Gogichaishvili Nana, Mandel Merle, Plaas Mario, Vasar EeroORCID, Loncke Jens, Vervliet Tim, Tsai Ting-Fen, Bultynck GeertORCID, Veksler Vladimir, Kaasik AllenORCID
Abstract
AbstractWolfram syndrome is a rare genetic disease caused by mutations in the WFS1 or CISD2 gene. A primary defect in Wolfram syndrome involves poor ER Ca2+ handling, but how this disturbance leads to the disease is not known. The current study, performed in primary neurons, the most affected and disease-relevant cells, involving both Wolfram syndrome genes, explains how the disturbed ER Ca2+ handling compromises mitochondrial function and affects neuronal health. Loss of ER Ca2+ content and impaired ER-mitochondrial contact sites in the WFS1- or CISD2-deficient neurons is associated with lower IP3R-mediated Ca2+ transfer from ER to mitochondria and decreased mitochondrial Ca2+ uptake. In turn, reduced mitochondrial Ca2+ content inhibits mitochondrial ATP production leading to an increased NADH/NAD+ ratio. The resulting bioenergetic deficit and reductive stress compromise the health of the neurons. Our work also identifies pharmacological targets and compounds that restore Ca2+ homeostasis, enhance mitochondrial function and improve neuronal health.
Publisher
Springer Science and Business Media LLC
Reference70 articles.
1. Rigoli, L. & Di Bella, C. Wolfram syndrome 1 and Wolfram syndrome 2. Curr. Opin. Pediatr. 24, 512–517 (2012). 2. Loncke, J., Vervliet, T., Parys, J. B., Kaasik, A. & Bultynck, G. Uniting the divergent Wolfram syndrome–linked proteins WFS1 and CISD2 as modulators of Ca2+ signaling. Sci. Signal. 14, eabc6165 (2021). 3. Barrett, T. et al. In GeneReviews(®) (eds. M. P. Adam, D. B. Everman, & G. M. Mirzaa et al.) (University of Washington, Seattle;1993-2022, 1993). 4. Barrett, T. G., Bundey, S. E. & Macleod, A. F. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 346, 1458–1463 (1995). 5. Delvecchio, M., Iacoviello, M., Pantaleo, A. & Resta, N. Clinical spectrum associated with wolfram syndrome type 1 and type 2: a review on genotype–phenotype correlations. Int. J. Environ. Res. Public Health 18, 4796 (2021).
|
|